| Seizures, Focal
Qudexy XR vs Xcopri
Side-by-side clinical, coverage, and cost comparison for seizures, focal.Deep comparison between: Qudexy vs Xcopri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXcopri has a higher rate of injection site reactions vs Qudexy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xcopri but not Qudexy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qudexy
Xcopri
At A Glance
Oral
Once daily
Broad-spectrum anticonvulsant
Oral
Once daily
Sodium channel inhibitor / GABA-A modulator
Indications
- Seizures, Focal
- Generalized seizures
- Lennox-Gastaut syndrome
- Migraine Disorders
- Seizures, Focal
Dosing
Seizures, Focal, Generalized seizures, Lennox-Gastaut syndrome Monotherapy (adults and peds >=10 years): 400 mg orally once daily, titrated over 6 weeks from 50 mg/day; peds 2-9 years: weight-based 150-400 mg/day once daily. Adjunctive (adults): 200 to 400 mg once daily; adjunctive (peds 2-16 years): approximately 5 to 9 mg/kg once daily, not to exceed 400 mg/day.
Migraine Disorders 100 mg orally once daily for patients 12 years of age and older, titrated over 4 weeks from 25 mg/day.
Seizures, Focal Initiate at 12.5 mg once daily and titrate every 2 weeks to recommended maintenance dose of 200 mg once daily (oral); maximum 400 mg once daily; for mild to moderate hepatic impairment, maximum 200 mg once daily.
Contraindications
- History of hypersensitivity reaction to topiramate, QUDEXY XR, or any inactive ingredient
- Hypersensitivity to cenobamate or any of the inactive ingredients in XCOPRI
- Familial Short QT syndrome
Adverse Reactions
Most common (>=10%) Paresthesia, somnolence, dizziness, weight loss, anorexia, speech disorders/related speech problems, psychomotor slowing, nervousness, vision abnormal
Serious Acute myopia and secondary angle closure glaucoma, visual field defects, oligohydrosis and hyperthermia, metabolic acidosis, suicidal behavior and ideation, cognitive/neuropsychiatric adverse reactions, decrease in bone mineral density, negative effects on growth, DRESS/multiorgan hypersensitivity, serious skin reactions, anaphylaxis and angioedema, hyperammonemia and encephalopathy, kidney stones, hypothermia with concomitant valproic acid
Postmarketing Hepatic failure, hepatitis, pancreatitis, bullous skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), pemphigus, maculopathy, nephrocalcinosis
Most common (>=10%) Somnolence, dizziness, fatigue, diplopia, headache
Serious DRESS/multiorgan hypersensitivity, QT shortening, suicidal behavior and ideation, liver injury, neurological adverse reactions
Postmarketing Psychosis (hallucinations, delusions/paranoia), hostility, aggression, hepatic failure
Pharmacology
Topiramate blocks voltage-dependent sodium channels, augments GABA-A receptor activity, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits carbonic anhydrase isozymes II and IV; the precise mechanisms underlying its anticonvulsant and preventive migraine effects are unknown.
Cenobamate reduces repetitive neuronal firing by inhibiting voltage-gated sodium currents and is also a positive allosteric modulator of the GABA-A ion channel; the precise mechanism by which these effects translate to seizure reduction in patients with partial-onset seizures is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qudexy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
Xcopri
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (2/12) · Qty limit (11/12)
UnitedHealthcare
Qudexy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xcopri
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (3/8) · Qty limit (2/8)
Humana
Qudexy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Xcopri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qudexy.
$20/momo
Xcopri Coupon CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QudexyView full Qudexy profile
XcopriView full Xcopri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.